The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue. The company has developed several world-first technologies since its inception, including wearable and implantable pacemakers, the implantable cardioverter-defibrillator (ICD), and remote patient monitoring systems. They also created miniaturized devices like the world's smallest pacemaker and spinal cord stimulator.
=== Primary === Raynaud's disease, or primary Raynaud's, is diagnosed if the symptoms are idiopathic, that is, if they occur by themselves and not in association with other diseases. Some refer to primary Raynaud's disease as "being allergic to coldness". It often develops in young women in their teens and early adulthood. Primary Raynaud's is thought to be at least partly hereditary. In a large genetic study two genes were identified that predispose for the condition: ADRA2A (alpha-2A-adrenergic receptor for adrenaline) and the transcription factor IRX1. Smoking increases the frequency and intensity of attacks, and a hormonal component exists. Caffeine, estrogen, and nonselective beta-blockers are often listed as aggravating factors, but evidence that they should be avoided is not solid.
Micelles form only when the concentration of surfactant is greater than the critical micelle concentration (CMC), and the temperature of the system is greater than the critical micelle temperature, or Krafft temperature. The formation of micelles can be understood using thermodynamics: Micelles can form spontaneously because of a balance between entropy and enthalpy. In water, the hydrophobic effect is the driving force for micelle formation, despite the fact that assembling surfactant molecules is unfavorable in terms of both enthalpy and entropy of the system. At very low concentrations of the surfactant, only monomers are present in solution. As the concentration of the surfactant is increased, a point is reached at which the unfavorable entropy contribution, from clustering the hydrophobic tails of the molecules, is overcome by a gain in entropy due to release of the solvation shells around the surfactant tails. At this point, the lipid tails of a part of the surfactants must be segregated from the water. Hence, they start to form micelles. In broad terms, above the CMC, the loss of entropy due to assembly of the surfactant molecules is less than the gain in entropy by setting free the water molecules that were "trapped" in the solvation shells of the surfactant monomers. Also important are enthalpic considerations, such as the electrostatic interactions that occur between the charged parts of surfactants.
=== National security === Xi has devoted a large amount of work towards national security, calling for the establishment of a holistic national security concept that encompasses "all aspects of the work of the party and the country." He introduced the concept in 2014, which he defined as taking "the security of the people as compass, political security as its roots, economic security as its pillar, military security and cultural security as its protections, and that relies on the promotion of international security." A new National Security Commission was formed in 2014 with Xi at its helm, centralizing national security decision-making. Since its creation by Xi, the National Security Commission has established local security committees, focusing on dissent. Believing it to be an important foundation of national security, Xi's administration has prioritized efforts to establish food security by pushing for as much as self-sufficiency in food as possible, while launching the Clean Plate campaign in 2013 and 2020 to combat food waste. He has additionally given priority to energy security; China is the world's largest energy consumer, having consumed more energy than the United States, the European Union and Japan combined in 2024. China has made heavy investments in its energy grid and designed policies to lessen dependence on foreign energy imports by investing in renewable energy as well as coal. Xi has championed the Fengqiao experience, calling on officials to contain and resolve conflicts at the grassroots level without needing to involve higher legal bodies.
== Lifetime == According to Vladimir Uglev, who headed a group that worked on the development of the Novichok agents, at least one liquid form of Novichok is very stable with a slow evaporation rate and can remain potent for possibly up to 50 years. Insufficient research has been conducted to fully understand its persistence in various situations in the environment.
Sources: en.wikipedia.org
=== Second half of 20th century === Several operational breakthroughs reshaped wholesaling and distribution globally. Large-scale distributors regained more control over distribution in many categories.:
DiCaprio continued to gain acclaim for his performances in the biopic The Aviator (2004), the political thriller Blood Diamond (2006), the crime thriller The Departed (2006), the romantic drama Revolutionary Road (2008), the action thriller Inception (2010), the western Django Unchained (2012), the biopic The Wolf of Wall Street (2013), the survival drama The Revenant (2015)—for which he won the Academy Award for Best Actor—the comedy-drama Once Upon a Time in Hollywood (2019), the crime drama Killers of the Flower Moon (2023) and the action film One Battle After Another (2025). DiCaprio is the founder of Appian Way Productions—a production company that has made some of his films and environmental documentaries, such as the series Greensburg (2008–2010)—and the Leonardo DiCaprio Foundation, a nonprofit organization devoted to promoting environmental awareness. A United Nations Messenger of Peace, he regularly supports charitable causes. In 2005, he was named a Commander of the Order of Arts and Letters for his contributions to the arts, and in 2016, he appeared in Time magazine's 100 most influential people in the world. DiCaprio was voted one of the 50 greatest actors of all time in a 2022 readers' poll by Empire magazine.
==== De-epithelialization technique ==== Labial reduction by means of the de-epithelialization of the tissues involves cutting the epithelium of a central area on the medial and lateral aspects of each labium minus (small lip), either with a scalpel or with a medical laser. This labiaplasty technique reduces the vertical excess tissue, whilst preserving the natural rugosity (corrugated free-edge) of the labia minora, and thus preserves the sensory and erectile characteristics of the labia. Yet, the technical disadvantage of de-epithelialization is that the width of the individual labium might increase if a large area of labial tissue must be de-epithelialized to achieve the labial reduction.
NMNAT enzymatic activity is probably essential at the cellular level, as complete ablation of NMNAT activity in model organisms leads to cellular inviability. NMNAT1 enhancement opposes the actions of SARM1 which would lead to axon degeneration, but this effect is not due to preventing SARM1 depletion of NAD+.
Sources: en.wikipedia.org
Hancock, David (2001). The Mastiffs: The Big Game Hunters – Their History, Development and Future. Ducklington, Oxon: Charwynne Dog Features. ISBN 9780951780114. Fogle, Bruce (2009). The Encyclopedia of the Dog. New York: DK Publishing. ISBN 978-0-7566-6004-8. Encyclopædia Britannica (2019). "Mastiff: breed of dog". www.britannica.com. Encyclopædia Britannica, Inc. Retrieved 9 September 2019. Parker, Heidi G. (2012). "Chapter 3: The history and relationship of dog breeds". In Ostrander, Elaine A.; Ruvinsky, Anatoly (eds.). The Genetics of the Dog. Wallingford, Oxfordshire: CAPI books. pp. 38–53. ISBN 9781845939403. Oxford Dictionaries (2019). "Mastiff". Lexico.com. Oxford University Press. Retrieved 9 September 2019. Wynn, M. B. (1886). History of the Mastiff: Gathered from Sculpture, Pottery, Carvings, Paintings and Engravings. Melton Mowbray, William Loxley. ISBN 978-1-4465-4892-9. {{cite book}}: ISBN / Date incompatibility (help) Young, Amy; Bannasch, Danika (2007). "Chapter 4: Morphological variation in the dog". In Ostrander, Elaine A.; Giger, Urs; Lindblad-Toh, Kerstin (eds.). The Dog and its Genome. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp. 47–66. ISBN 9780879697815.
=== Authorizations of COVID-19 vaccines === The COVID-19 pandemic, and sequencing of the causative virus SARS-CoV-2 at the beginning of 2020, led to the rapid development of the first approved mRNA vaccines. BioNTech and Moderna in December of the same year obtained approval for their mRNA-based COVID-19 vaccines. In December 2020, the UK Medicines and Healthcare products Regulatory Agency (MHRA) became the first global medicines regulator in history to approve an mRNA vaccine, granting emergency authorization for Pfizer–BioNTech's BNT162b2 COVID-19 vaccine for widespread use. Also, in December 2020, the US Food and Drug Administration gave emergency use authorization for the Pfizer–BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.
Last but not least, specific cleavage of poly (ADP-ribose) polymerase (PARP) and a decrease in pro-caspase9 and 3 were also induced by arenobufagin treatment. PARP is mainly involved in cell repair and programmed cell death. After treatment with arenobufagin, some cells make more autophagosomes and lysosomes, whereas other cells undergo apoptosis. Arenobufagin also leads to increased expression of LC3-II, Biclin1(initial vesicle formation), Atg5 (elongation and completion), Atg9, Atg16L1 and p62/SQSTM1, all proteins which induce autophagy. Blockers of autophagy increase the cytotoxic effect of arenobufagin. Addition of 3-MA increases the proportion of cells in which there in enlarged PARP cleavage and limited caspase-9 and caspase-3 cleavage. This indicates that autophagy pathways protect the cell against apoptosis by arenobufagin. It was hypothesized that arenobufagin may inhibit the PI3K/Akt pathway in controlling cell death and differentiation in response to external stimuli. It was found that arenobufagin inhibited the proteins Akt, PDK1 and PI3K, whereas it stimulated the PHEN-protein. It does this by altering the degree of phosphorylation. All these proteins are involved in the PI3/Akt pathway. Further down the pathway, arenobufagin indirectly inhibits the mTOR-protein, which is involved in apoptosis as well as in autophagy. The biotransformation of arenobufagin by Alternaria alternata leads to the following three metabolites: 3-oxo-arenobufagin (1a), ψ-bufarenogin (1b), and 3- oxo- ψ-bufarenogin (1c).
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.